U.S. markets closed

FDG Electric Vehicles Limited (CAOHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.12000.0000 (0.00%)
At close: 2:30PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1200
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1200 - 0.1200
52 Week Range0.0180 - 2.0000
Volume1,045
Avg. Volume2,648
Market Cap300.57M
Beta (5Y Monthly)-6.64
PE Ratio (TTM)N/A
EPS (TTM)-0.1580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

    Natural Health Products Will Be Manufactured and Packaged at the Company's New FacilityVANCOUVER, BC / ACCESSWIRE / May 19, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a production and supply agreement (the "Agreement") with Lobe Sciences Ltd.

  • ACCESSWIRE

    HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches

    HAVN Life works towards substantiating a patent application and preclinical workVANCOUVER, BC / ACCESSWIRE / May 17, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has entered into a definitive agreement to acquire clinical stage intellectual property ("IP") from Bolt Therapeutics (the "Acquisition").

  • ACCESSWIRE

    Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit

    Havn Life will join 80+ other small cap and micro-cap companies at leading event for investorsVANCOUVER, BC / ACCESSWIRE / May 14, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that CEO Tim Moore will attend the Q2 Virtual Investor Summit.